Revised Recommendations of the Consortium of MS Centers Task Force for a Standardized MRI Protocol and Clinical Guidelines for the Diagnosis and Follow-Up of Multiple Sclerosis

This is a comprehensive group of guidelines for imaging patients with demyelinating disease, from an international group of neurologists and radiologists. Suggestions for MR imaging protocols are given for the brain, for surveillance imaging for progressive multifocal leukoencephalopathy, for spinal cord imaging, and for the orbit. Recommendations are also given for what type of material should be included in the report. SUMMARY: An international group of neurologists and radiologists developed revised guidelines for standardized brain and spinal cord MR imaging for the diagnosis and follow-up of MS. A brain MR imaging with gadolinium is recommended for the diagnosis of MS. A spinal cord MR imaging is recommended if the brain MR imaging is nondiagnostic or if the presenting symptoms are at the level of the spinal cord. A follow-up brain MR imaging with gadolinium is recommended to demonstrate dissemination in time and ongoing clinically silent disease activity while on treatment, to evaluate unexpected clinical worsening, to re-assess the original diagnosis, and as a new baseline before starting or modifying therapy. A routine brain MR imaging should be considered every 6 months to 2 years for all patients with relapsing MS. The brain MR imaging protocol includes 3D T1-weighted, 3D T2-FLAIR, 3D T2-weighted, post-single-dose gadolinium-enhanced T1-weighted sequences, and a DWI sequence. The progressive multifocal leukoencephalopathy surveillance protocol includes FLAIR and DWI sequences only. The spinal cord MR imaging protocol includes sagittal T1-weighted and proton attenuation, STIR or phase-sensitive inversion recovery, axial T2- or T2*-weighted imaging through suspicious lesions, and, in some cases, postcontrast gadolinium-enhanced T1-weighted imaging. The clinical question being addressed should be provided in the requisition for the MR imaging. The radiology report should be descriptive, with results referenced to previous studies. MR imaging studies should be permanently retained and available. The current revision incorporates new clinical information and imaging techniques that have become more available.

[1]  A. Traboulsee,et al.  International consensus diagnostic criteria for neuromyelitis optica spectrum disorders , 2015, Neurology.

[2]  S. Maderwald,et al.  Diagnostic value of 3D fluid attenuated inversion recovery sequence in multiple sclerosis , 2015, Acta radiologica.

[3]  James McIninch,et al.  Outcome and survival of asymptomatic PML in natalizumab-treated MS patients , 2014, Annals of clinical and translational neurology.

[4]  F. Barkhof,et al.  Diagnosis of natalizumab-associated progressive multifocal leukoencephalopathy using MRI. , 2014, Current opinion in neurology.

[5]  R. Rudick,et al.  Simple MRI Metrics Contribute to Optimal Care of the Patient with Multiple Sclerosis , 2014, American Journal of Neuroradiology.

[6]  M. Eliasziw,et al.  Application and a proposed modification of the 2010 McDonald criteria for the diagnosis of multiple sclerosis in a Canadian cohort of patients with clinically isolated syndromes , 2014, Multiple sclerosis.

[7]  À. Rovira,et al.  Radiologically Isolated Syndrome: 5-Year Risk for an Initial Clinical Event , 2014, PloS one.

[8]  F. Barkhof,et al.  Long-term impact of interferon beta-1b in patients with CIS: 8-year follow-up of BENEFIT , 2013, Journal of Neurology, Neurosurgery & Psychiatry.

[9]  M. Rovaris Faculty Opinions recommendation of Predictors of long-term outcome in multiple sclerosis patients treated with interferon β. , 2013 .

[10]  Douglas L Arnold,et al.  Treatment Optimization in MS: Canadian MS Working Group Updated Recommendations , 2013, Canadian Journal of Neurological Sciences / Journal Canadien des Sciences Neurologiques.

[11]  B Stubinski,et al.  Scoring treatment response in patients with relapsing multiple sclerosis , 2013, Multiple sclerosis.

[12]  Peter Reimer,et al.  Nephrogenic systemic fibrosis and gadolinium-based contrast media: updated ESUR Contrast Medium Safety Committee guidelines , 2013, European Radiology.

[13]  R. Rudick,et al.  Predictors of long‐term outcome in multiple sclerosis patients treated with interferon beta , 2013, Annals of neurology.

[14]  F. Barkhof,et al.  Spinal cord lesions in patients with clinically isolated syndrome , 2013, Neurology.

[15]  F. Fazekas,et al.  Recommendations to improve imaging and analysis of brain lesion load and atrophy in longitudinal studies of multiple sclerosis , 2012, Journal of Neurology.

[16]  M. Filippi,et al.  Magnetic resonance imaging pattern in natalizumab‐associated progressive multifocal leukoencephalopathy , 2012, Annals of neurology.

[17]  Meena Subramanyam,et al.  Risk of natalizumab-associated progressive multifocal leukoencephalopathy. , 2012, The New England journal of medicine.

[18]  D. Bluemke,et al.  Gadolinium-enhanced cardiovascular magnetic resonance: administered dose in relationship to united states food and drug administration (FDA) guidelines , 2012, Journal of Cardiovascular Magnetic Resonance.

[19]  Jeffrey A. Cohen,et al.  Diagnostic criteria for multiple sclerosis: 2010 Revisions to the McDonald criteria , 2011, Annals of neurology.

[20]  D. Goodin,et al.  Asymptomatic spinal cord lesions predict disease progression in radiologically isolated syndrome , 2011, Neurology.

[21]  F. Moore INCIDENTAL MRI ANOMALIES SUGGESTIVE OF MULTIPLE SCLEROSIS: THE RADIOLOGICALLY ISOLATED SYNDROME , 2009, Neurology.

[22]  C. Pozzilli,et al.  One‐year MRI scan predicts clinical response to interferon beta in multiple sclerosis , 2009, European journal of neurology.

[23]  P. Calabresi,et al.  Rituximab in patients with primary progressive multiple sclerosis: Results of a randomized double‐blind placebo‐controlled multicenter trial , 2009, Annals of neurology.

[24]  J Sastre-Garriga,et al.  Measures in the first year of therapy predict the response to interferon β in MS , 2009, Multiple sclerosis.

[25]  F. Barkhof,et al.  High field MRI in the diagnosis of multiple sclerosis: high field–high yield? , 2009, Neuroradiology.

[26]  Luca Roccatagliata,et al.  Magnetic resonance imaging as a potential surrogate for relapses in multiple sclerosis: A meta‐analytic approach , 2009, Annals of neurology.

[27]  Anthony Traboulsee,et al.  Conventional MR imaging. , 2008, Neuroimaging clinics of North America.

[28]  Jeffrey A. Cohen,et al.  Differential diagnosis of suspected multiple sclerosis: a consensus approach , 2008, Multiple sclerosis.

[29]  P. Rieckmann,et al.  Basic and escalating immunomodulatory treatments in multiple sclerosis: Current therapeutic recommendations , 2008, Journal of Neurology.

[30]  Melvin Greer,et al.  Multiple sclerosis risk after optic neuritis: final optic neuritis treatment trial follow-up. , 2008, Archives of neurology.

[31]  A. Thompson,et al.  Disability and T2 MRI lesions: a 20-year follow-up of patients with relapse onset of multiple sclerosis. , 2008, Brain : a journal of neurology.

[32]  David H. Miller,et al.  MRI and the diagnosis of multiple sclerosis: expanding the concept of “no better explanation” , 2006, The Lancet Neurology.

[33]  R. Rudick,et al.  Significance of T2 lesions in multiple sclerosis: A 13‐year longitudinal study , 2006, Annals of neurology.

[34]  J A Frank,et al.  Standardized MR imaging protocol for multiple sclerosis: Consortium of MS Centers consensus guidelines. , 2006, AJNR. American journal of neuroradiology.

[35]  F. Barkhof,et al.  Spinal cord abnormalities in recently diagnosed MS patients , 2004, Neurology.

[36]  A J Thompson,et al.  The longitudinal relation between brain lesion load and atrophy in multiple sclerosis: a 14 year follow up study , 2003, Journal of neurology, neurosurgery, and psychiatry.

[37]  F. Jolesz,et al.  MRI contrast uptake in new lesions in relapsing-remitting MS followed at weekly intervals , 2003, Neurology.

[38]  David H. Miller,et al.  Application of the new McDonald criteria to patients with clinically isolated syndromes suggestive of multiple sclerosis , 2002, Annals of neurology.

[39]  S. Cole,et al.  Interferon β‐1a for early multiple sclerosis: CHAMPS trial subgroup analyses , 2002 .

[40]  A. Compston,et al.  Recommended diagnostic criteria for multiple sclerosis: Guidelines from the international panel on the diagnosis of multiple sclerosis , 2001, Annals of neurology.

[41]  F Barkhof,et al.  T1 hypointensities and axonal loss. , 2000, Neuroimaging clinics of North America.

[42]  N. Patronas,et al.  Serial gadolinium‐enhanced magnetic resonance imaging scans in patients with early, relapsing‐remitting multiple sclerosis: Implications for clinical trials and natural history , 1991, Annals of neurology.

[43]  B E Kendall,et al.  Serial gadolinium enhanced magnetic resonance imaging in multiple sclerosis. , 1988, Brain : a journal of neurology.

[44]  B. Waksman A multiple sclerosis therapy? , 1987, Nature.

[45]  D. Silberberg,et al.  New diagnostic criteria for multiple sclerosis: Guidelines for research protocols , 1983, Annals of neurology.

[46]  R. Sergott Multiple Sclerosis Risk After Optic Neuritis: Final Optic Neuritis Treatment Trial Follow-up , 2009 .

[47]  P. Narayana,et al.  Cervical Spinal Cord Lesions in Multiple Sclerosis: T1-weighted Inversion-Recovery MR Imaging with Phase-Sensitive Reconstruction. , 2008, Radiology.

[48]  Hompson,et al.  A LONGITUDINAL STUDY OF ABNORMALITIES ON MRI AND DISABILITY FROM MULTIPLE SCLEROSIS , 2002 .

[49]  S. Cole,et al.  Interferon beta-1a for early multiple sclerosis: CHAMPS trial subgroup analyses. , 2002, Annals of neurology.

[50]  U. Schmiedl,et al.  Lesion enhancement in radio-frequency spoiled gradient-echo imaging: theory, experimental evaluation, and clinical implications. , 1994, AJNR. American journal of neuroradiology.